Research analysts at Guggenheim initiated coverage on shares of Sienna Biopharmaceuticals (NASDAQ:SNNA) in a research report issued on Tuesday, The Fly reports. The firm set a “neutral” rating on the stock.

Several other research firms have also recently weighed in on SNNA. Cowen began coverage on Sienna Biopharmaceuticals in a report on Monday, August 21st. They issued an “outperform” rating and a $50.00 price objective for the company. J P Morgan Chase & Co began coverage on Sienna Biopharmaceuticals in a report on Monday, August 21st. They issued an “overweight” rating and a $28.00 price objective for the company. Finally, BMO Capital Markets began coverage on Sienna Biopharmaceuticals in a report on Monday, August 21st. They issued an “outperform” rating and a $30.00 price objective for the company.

Sienna Biopharmaceuticals (NASDAQ:SNNA) traded down $0.32 during midday trading on Tuesday, reaching $20.53. The company’s stock had a trading volume of 16,300 shares, compared to its average volume of 68,436. Sienna Biopharmaceuticals has a 1-year low of $15.22 and a 1-year high of $29.25.

Sienna Biopharmaceuticals (NASDAQ:SNNA) last released its quarterly earnings data on Thursday, September 7th. The company reported ($6.50) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($5.82). sell-side analysts forecast that Sienna Biopharmaceuticals will post -2.1 earnings per share for the current year.

In other Sienna Biopharmaceuticals news, Director Dennis M. Fenton acquired 1,250 shares of the company’s stock in a transaction on Monday, September 18th. The stock was acquired at an average price of $22.96 per share, for a total transaction of $28,700.00. Following the acquisition, the director now owns 1,250 shares in the company, valued at approximately $28,700. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Victory Capital Management Inc. purchased a new position in shares of Sienna Biopharmaceuticals in the 3rd quarter valued at approximately $10,198,000. Bank of New York Mellon Corp purchased a new position in shares of Sienna Biopharmaceuticals in the 3rd quarter valued at approximately $274,000. TimesSquare Capital Management LLC purchased a new position in shares of Sienna Biopharmaceuticals in the 3rd quarter valued at approximately $8,571,000. Citadel Advisors LLC purchased a new position in shares of Sienna Biopharmaceuticals in the 3rd quarter valued at approximately $440,000. Finally, California State Teachers Retirement System purchased a new position in shares of Sienna Biopharmaceuticals in the 3rd quarter valued at approximately $182,000. Institutional investors and hedge funds own 39.29% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/05/sienna-biopharmaceuticals-snna-earns-neutral-rating-from-analysts-at-guggenheim.html.

Sienna Biopharmaceuticals Company Profile

Sienna Biopharmaceuticals, Inc is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125.

The Fly

Receive News & Ratings for Sienna Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.